Year All202420232022202120202019 Oct 21, 2021 Verve Therapeutics to Participate in the Jefferies Gene Therapy/Editing Summit Sep 27, 2021 Verve Therapeutics to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference Sep 23, 2021 Verve Therapeutics Announces Development of Proprietary GalNAc-LNP Delivery Technology Enabling Efficient In Vivo Liver Delivery of Base Editors Sep 23, 2021 Verve Therapeutics Reports New Preclinical Data with VERVE-101 Demonstrating Robust, Durable and Precise Editing of the PCSK9 Gene for the Treatment of Cardiovascular Disease Aug 12, 2021 Verve Therapeutics Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results Jun 21, 2021 Verve Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Jun 16, 2021 Verve Therapeutics Announces Pricing of Initial Public Offering Jun 01, 2021 Verve Therapeutics Appoints Leading Biotechnology Executive Michael MacLean to its Board of Directors May 19, 2021 Verve Therapeutics Announces Nature Publication Highlighting its Use of Base Editing to Potently and Durably Lower Blood PCSK9 and LDL-C in Non-Human Primates May 11, 2021 Verve Therapeutics to Present Preclinical Data from Gene Editing Programs for the Treatment of Atherosclerotic Cardiovascular Disease at ASGCT
Sep 27, 2021 Verve Therapeutics to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference
Sep 23, 2021 Verve Therapeutics Announces Development of Proprietary GalNAc-LNP Delivery Technology Enabling Efficient In Vivo Liver Delivery of Base Editors
Sep 23, 2021 Verve Therapeutics Reports New Preclinical Data with VERVE-101 Demonstrating Robust, Durable and Precise Editing of the PCSK9 Gene for the Treatment of Cardiovascular Disease
Aug 12, 2021 Verve Therapeutics Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results
Jun 21, 2021 Verve Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Jun 01, 2021 Verve Therapeutics Appoints Leading Biotechnology Executive Michael MacLean to its Board of Directors
May 19, 2021 Verve Therapeutics Announces Nature Publication Highlighting its Use of Base Editing to Potently and Durably Lower Blood PCSK9 and LDL-C in Non-Human Primates
May 11, 2021 Verve Therapeutics to Present Preclinical Data from Gene Editing Programs for the Treatment of Atherosclerotic Cardiovascular Disease at ASGCT
